Is THC a Buy or a Sell? The Bull and Bear Case (2026)
Last updated October 2026
Short answer
Both cases are real, which is why the question is contested. The bull case for Tenet Healthcare (THC) rests on USPI ambulatory surgery leadership: United Surgical Partners International is the largest ambulatory surgery center platform in the United States, with interests in more than 500 surgery centers and over two dozen surgical hospitals. The bear case rests on hospital operators face reimbursement pressure from Medicare, Medicaid, and commercial payers, and changes to Affordable Care Act exchange subsidies could pressure volumes and payer mix. Analysts covering it publish targets from $260.00 to $315.00 against a $267.25 price, so even the professionals disagree by 19% of their own average. We do not give a verdict. What follows is each case at full strength, so you can decide which set of assumptions you actually believe. Walnut is not an investment adviser.
Tenet Healthcare is a diversified for-profit healthcare services company that operates through three segments. Hospital Operations runs acute care and specialty hospitals plus affiliated outpatient facilities, imaging centers, and physician practices. United Surgical Partners International (USPI) is the ambulatory segment and operates or holds interests in hundreds of ambulatory surgery centers and surgical hospitals across dozens of states, making it the largest ASC platform in the country. Conifer Health Solutions provides revenue cycle management and value-based care services to hospitals and health systems. The investment story has shifted toward USPI, which benefits from the secular migration of surgical procedures out of expensive inpatient settings into lower-cost outpatient centers. USPI carries higher margins and grows faster than the hospital base, and Tenet has been acquiring additional surgery centers to expand it. Alongside that mix shift, management has cut debt, reduced interest expense, and earned credit-rating upgrades, which has lifted earnings per share and supported the stock. Founded in 1969 and headquartered in Dallas, Texas, Tenet trades on the NYSE and is a member of the S&P 500. The 2026 numbers have kept beating expectations. Second-quarter revenue was about $5.63 billion, up roughly 7% year over year, and adjusted EPS of $6.12 came in far above the $4.26 consensus, the fourth consecutive quarterly beat; net income attributable to Tenet reached about $826 million in the quarter. Over the trailing twelve months revenue is about $21.8 billion and net income about $2.24 billion. The stock has followed: THC closed at $269.84 on October 16, 2026, up about 35% year to date and 37% over three months, close to its 52-week high of about $283. Third-quarter results are scheduled for October 29, 2026, with consensus near $4.67 of EPS on $5.51 billion of revenue.
The bull case: what would have to be true for $315.00
The most optimistic published target on THC is $315.00, +17.9% from the $267.25 price as of October 2026. Getting there needs the following to work close to its best case, not merely to avoid going wrong.
1. USPI ambulatory surgery leadership.
United Surgical Partners International is the largest ambulatory surgery center platform in the United States, with interests in more than 500 surgery centers and over two dozen surgical hospitals. USPI grows faster and at higher margins than the hospital base and rides the multi-year shift of procedures from inpatient to outpatient settings. Same-facility surgical revenue and net revenue per case have been growing at healthy rates.
2. Business mix shift toward higher-margin services.
Tenet has sold hospitals and reinvested in USPI, tilting the revenue mix toward the higher-margin ambulatory business. This mix shift, combined with disciplined expense management and acquisitions of new centers, has expanded consolidated EBITDA margins well above historical hospital-operator norms.
3. Deleveraging and improved earnings quality.
Management has prioritized reducing debt, cutting interest expense, and returning capital through buybacks. Sustained deleveraging and EBITDA strength have driven credit-rating upgrades, and lower interest expense has compounded strong earnings-per-share growth over the past two years. Debt remains substantial at about $13.25 billion against about $2.17 billion of cash as of mid-2026, but trailing free cash flow of roughly $2.25 billion gives the company room to keep paying it down and repurchasing shares.
4. Conifer revenue cycle services.
Conifer Health Solutions provides revenue cycle management, patient communications, and value-based care support to hospitals and health systems, including Tenet's own facilities and third-party clients. It is a smaller, steadier services contributor that diversifies Tenet away from pure patient-care revenue.
The bear case: what would have to be true for $260.00
The most pessimistic published target is $260.00, -2.7% from the current price. That is not a floor and not a forecast; it is roughly what one analyst thinks Tenet Healthcare is worth if the risks below bite instead of the drivers above.
Hospital operators face reimbursement pressure from Medicare, Medicaid, and commercial payers, and changes to Affordable Care Act exchange subsidies could pressure volumes and payer mix. Labor costs, physician and nurse staffing, and wage inflation weigh on the hospital segment. The company still carries meaningful debt despite deleveraging, so higher-for-longer interest rates matter. Bad debt from uninsured and underinsured patients, regulatory and billing scrutiny, and cyclicality in elective surgical volumes are additional risks. Acquisition-led USPI growth depends on continued access to attractive surgery-center deals at reasonable prices. After a roughly 35% gain in 2026, expectations are higher too: consensus calls for 2027 EPS of about $21.08, slightly below the roughly $21.22 expected for 2026, so the market is not pricing in another year of rapid earnings growth, and a stumble against that bar could weigh on the shares.
The bear case deserves the same attention as the bull case, and usually gets less. If you are holding THC already, the question is not whether these risks exist but whether any of them has moved from possible to actually happening in the reported numbers.
Where analysts land on THC
22 analysts cover THC, with an average target of $285.32 (+6.8% against $267.25) and a split of 19 buy, 4 hold, 0 sell. Bear in mind sell-side ratings skew positive across the whole market, so that split is not a balanced vote. The full target table, the recent rating actions by firm, and how the consensus has shifted are on the THC forecast and price target page.
How is THC valued? (as of October 2026)
Snapshot for THC as of October 2026, sourced from Yahoo Finance and may be delayed. Valuation figures move with price and earnings; verify the current numbers with your broker before deciding.
- Revenue (TTM): ~$21.8 billion (Q2 2026 +~7% yoy)
- Q2 2026 adjusted EPS: ~$6.12 vs ~$4.26 est.
- Net income (TTM): ~$2.24 billion (net margin ~10%)
- Operating margin (TTM): ~18%
- P/E (trailing / forward): ~10x / ~13x
- EV/EBITDA: ~7.7x
- Market cap: ~$21.7 billion
- Dividend yield: None
Tenet still trades at a modest earnings multiple typical of hospital operators (a discount that prices in reimbursement and leverage risk), even after a 35% rise in 2026 as USPI mix shift, margin gains, and deleveraging improved earnings quality. The forward P/E near 13x sits above the trailing figure because analysts expect 2027 EPS of about $21, roughly flat with 2026, after a run of large beats. Third-quarter results on October 29, 2026 will show whether the outperformance continues.
How do you decide if THC is a buy?
Rather than asking whether THC is a buy in the abstract, it tends to help to answer four questions:
- Thesis: do you believe the bull case above, and is it still true today?
- Time horizon: a single stock can be volatile, so a longer horizon absorbs more of the swings.
- Position sizing: a thesis can be right and the sizing still wrong; decide how much of your portfolio one name should be.
- Overlap: check whether you already hold THC indirectly through an index or sector ETF before adding more.
What would change your mind on THC
Write the tripwires down before you need them. Deciding what would falsify your view is far harder once a position is moving against you.
- Bull case breaks if: USPI ambulatory surgery leadership stalls in the reported numbers rather than in the narrative around them.
- Bear case breaks if: hospital operators face reimbursement pressure from Medicare, Medicaid, and commercial payers, and changes to Affordable Care Act exchange subsidies could pressure volumes and payer mix fails to materialise over several reporting periods while the drivers keep compounding.
- Neither matters if: the position has grown large enough that being wrong would damage the whole portfolio. Sizing overrides the argument.
For the full picture, see the THC stock guide (what the company does, the ETFs that hold it, similar stocks, and the themes it fits). In Walnut you can ask its AI about THC against your real portfolio and see your actual exposure before deciding.
Investing in Tenet Healthcare with AI
Connect the broker you already use and ask Walnut's AI how THC fits what you actually hold: whether you own it already through a fund, what it would do to your concentration, and how it has tracked the S&P 500. Read-only by default, and you approve anything before it reaches your broker.
FAQ
Is THC a good stock to buy right now?
+
That depends on which case you find more convincing, and both are on this page. The bull case rests on USPI ambulatory surgery leadership, with revenue (ttm) at ~$21.8 billion (Q2 2026 +~7% yoy). The bear case rests on hospital operators face reimbursement pressure from Medicare, Medicaid, and commercial payers, and changes to Affordable Care Act exchange subsidies could pressure volumes and payer mix. Analysts covering it are spread from $260.00 to $315.00, which is itself a signal that this is genuinely contested. If you believe the thesis, the real questions become sizing and overlap rather than timing. Walnut is not an investment adviser and this is not a recommendation.
Should I sell THC?
+
Nobody can answer that for you, and the honest version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. Hospital operators face reimbursement pressure from Medicare, Medicaid, and commercial payers, and changes to Affordable Care Act exchange subsidies could pressure volumes and payer mix. If that risk is what you were worried about and it is now playing out, that is a real signal. If the price simply fell while the thesis held, that is a different situation entirely. The most pessimistic published target is $260.00, -2.7% from the $267.25 price, which is one analyst's downside case rather than a floor. Walnut is not an investment adviser.
What is the bull case for THC?
+
USPI ambulatory surgery leadership. United Surgical Partners International is the largest ambulatory surgery center platform in the United States, with interests in more than 500 surgery centers and over two dozen surgical hospitals. The most optimistic analyst target on THC is $315.00, +17.9% from the $267.25 price. That figure is only reachable if this thesis works close to its best case.
What is the bear case for THC?
+
Hospital operators face reimbursement pressure from Medicare, Medicaid, and commercial payers, and changes to Affordable Care Act exchange subsidies could pressure volumes and payer mix. Labor costs, physician and nurse staffing, and wage inflation weigh on the hospital segment. The company still carries meaningful debt despite deleveraging, so higher-for-longer interest rates matter. Bad debt from uninsured and underinsured patients, regulatory and billing scrutiny, and cyclicality in elective surgical volumes are additional risks. Acquisition-led USPI growth depends on continued access to attractive surgery-center deals at reasonable prices. After a roughly 35% gain in 2026, expectations are higher too: consensus calls for 2027 EPS of about $21.08, slightly below the roughly $21.22 expected for 2026, so the market is not pricing in another year of rapid earnings growth, and a stumble against that bar could weigh on the shares. The most pessimistic published target is $260.00, -2.7% from the current price, which is roughly what the stock is worth if these risks bite rather than the drivers.
What does Tenet Healthcare do?
+
Tenet Healthcare is a diversified for-profit healthcare services company that operates through three segments.
What would have to change for THC to stop being worth holding?
+
Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (USPI ambulatory surgery leadership) stalling in the reported numbers rather than in the narrative, the risk above (hospital operators face reimbursement pressure from Medicare, Medicaid, and commercial payers, and changes to Affordable Care Act exchange subsidies could pressure volumes and payer mix) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.
What is Tenet Healthcare's ticker symbol?
+
THC, listed on the New York Stock Exchange. Officially Tenet Healthcare Corporation, founded in 1969 and headquartered in Dallas, Texas. It trades during US market hours and is available at every major US brokerage, including as fractional shares at brokers that support them.
What does Tenet Healthcare do?
+
Tenet is a for-profit healthcare services company with three segments. Hospital Operations runs acute care and specialty hospitals plus affiliated outpatient facilities. United Surgical Partners International (USPI) operates the largest ambulatory surgery center platform in the United States. Conifer Health Solutions provides revenue cycle management and value-based care services to hospitals.
Who are Tenet Healthcare's competitors?
+
In hospitals, the main peers are HCA Healthcare, Community Health Systems, and Universal Health Services. In ambulatory surgery, Surgery Partners is the closest public comparable to USPI, and HCA also runs a large outpatient footprint. In revenue cycle services, Conifer competes with firms such as R1 RCM.
Walnut is informational, not investment advice, and gives no verdict on THC. Analyst targets referenced here come from a October 2026 pull of published third-party research and change constantly. Verify current figures with your broker before acting on them.